Cargando…
S139: INTERIM ANALYSIS OF A REGISTRATION ENABLING STUDY OF PIVEKIMAB SUNIRINE (PVEK, IMGN632) A CD123-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428302/ http://dx.doi.org/10.1097/01.HS9.0000967468.85099.f4 |
| _version_ | 1785090435232825344 |
|---|---|
| author | Pemmaraju, Naveen Martinelli, Giovanni Montesinos, Pau Mazzarella, Luca Deangelo, Daniel J. Erba, Harry Sweet, Kendra Walter, Roland Deconinck, Eric Legrand, Ollivier Wang, Eunice Aribi, Ahmed Ulrickson, Matthew Marconi, Giovanni Lane, Andrew Kantarjian, Hagop Sloss, Callum Malcolm, Kara Zweidler-Mckay, Patrick Daver, Naval |
| author_facet | Pemmaraju, Naveen Martinelli, Giovanni Montesinos, Pau Mazzarella, Luca Deangelo, Daniel J. Erba, Harry Sweet, Kendra Walter, Roland Deconinck, Eric Legrand, Ollivier Wang, Eunice Aribi, Ahmed Ulrickson, Matthew Marconi, Giovanni Lane, Andrew Kantarjian, Hagop Sloss, Callum Malcolm, Kara Zweidler-Mckay, Patrick Daver, Naval |
| author_sort | Pemmaraju, Naveen |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428302 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104283022023-08-17 S139: INTERIM ANALYSIS OF A REGISTRATION ENABLING STUDY OF PIVEKIMAB SUNIRINE (PVEK, IMGN632) A CD123-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) Pemmaraju, Naveen Martinelli, Giovanni Montesinos, Pau Mazzarella, Luca Deangelo, Daniel J. Erba, Harry Sweet, Kendra Walter, Roland Deconinck, Eric Legrand, Ollivier Wang, Eunice Aribi, Ahmed Ulrickson, Matthew Marconi, Giovanni Lane, Andrew Kantarjian, Hagop Sloss, Callum Malcolm, Kara Zweidler-Mckay, Patrick Daver, Naval Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428302/ http://dx.doi.org/10.1097/01.HS9.0000967468.85099.f4 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Sessions Pemmaraju, Naveen Martinelli, Giovanni Montesinos, Pau Mazzarella, Luca Deangelo, Daniel J. Erba, Harry Sweet, Kendra Walter, Roland Deconinck, Eric Legrand, Ollivier Wang, Eunice Aribi, Ahmed Ulrickson, Matthew Marconi, Giovanni Lane, Andrew Kantarjian, Hagop Sloss, Callum Malcolm, Kara Zweidler-Mckay, Patrick Daver, Naval S139: INTERIM ANALYSIS OF A REGISTRATION ENABLING STUDY OF PIVEKIMAB SUNIRINE (PVEK, IMGN632) A CD123-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) |
| title | S139: INTERIM ANALYSIS OF A REGISTRATION ENABLING STUDY OF PIVEKIMAB SUNIRINE (PVEK, IMGN632) A CD123-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) |
| title_full | S139: INTERIM ANALYSIS OF A REGISTRATION ENABLING STUDY OF PIVEKIMAB SUNIRINE (PVEK, IMGN632) A CD123-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) |
| title_fullStr | S139: INTERIM ANALYSIS OF A REGISTRATION ENABLING STUDY OF PIVEKIMAB SUNIRINE (PVEK, IMGN632) A CD123-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) |
| title_full_unstemmed | S139: INTERIM ANALYSIS OF A REGISTRATION ENABLING STUDY OF PIVEKIMAB SUNIRINE (PVEK, IMGN632) A CD123-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) |
| title_short | S139: INTERIM ANALYSIS OF A REGISTRATION ENABLING STUDY OF PIVEKIMAB SUNIRINE (PVEK, IMGN632) A CD123-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) |
| title_sort | s139: interim analysis of a registration enabling study of pivekimab sunirine (pvek, imgn632) a cd123-targeting antibody-drug conjugate, in patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn) |
| topic | Oral Sessions |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428302/ http://dx.doi.org/10.1097/01.HS9.0000967468.85099.f4 |
| work_keys_str_mv | AT pemmarajunaveen s139interimanalysisofaregistrationenablingstudyofpivekimabsunirinepvekimgn632acd123targetingantibodydrugconjugateinpatientswithblasticplasmacytoiddendriticcellneoplasmbpdcn AT martinelligiovanni s139interimanalysisofaregistrationenablingstudyofpivekimabsunirinepvekimgn632acd123targetingantibodydrugconjugateinpatientswithblasticplasmacytoiddendriticcellneoplasmbpdcn AT montesinospau s139interimanalysisofaregistrationenablingstudyofpivekimabsunirinepvekimgn632acd123targetingantibodydrugconjugateinpatientswithblasticplasmacytoiddendriticcellneoplasmbpdcn AT mazzarellaluca s139interimanalysisofaregistrationenablingstudyofpivekimabsunirinepvekimgn632acd123targetingantibodydrugconjugateinpatientswithblasticplasmacytoiddendriticcellneoplasmbpdcn AT deangelodanielj s139interimanalysisofaregistrationenablingstudyofpivekimabsunirinepvekimgn632acd123targetingantibodydrugconjugateinpatientswithblasticplasmacytoiddendriticcellneoplasmbpdcn AT erbaharry s139interimanalysisofaregistrationenablingstudyofpivekimabsunirinepvekimgn632acd123targetingantibodydrugconjugateinpatientswithblasticplasmacytoiddendriticcellneoplasmbpdcn AT sweetkendra s139interimanalysisofaregistrationenablingstudyofpivekimabsunirinepvekimgn632acd123targetingantibodydrugconjugateinpatientswithblasticplasmacytoiddendriticcellneoplasmbpdcn AT walterroland s139interimanalysisofaregistrationenablingstudyofpivekimabsunirinepvekimgn632acd123targetingantibodydrugconjugateinpatientswithblasticplasmacytoiddendriticcellneoplasmbpdcn AT deconinckeric s139interimanalysisofaregistrationenablingstudyofpivekimabsunirinepvekimgn632acd123targetingantibodydrugconjugateinpatientswithblasticplasmacytoiddendriticcellneoplasmbpdcn AT legrandollivier s139interimanalysisofaregistrationenablingstudyofpivekimabsunirinepvekimgn632acd123targetingantibodydrugconjugateinpatientswithblasticplasmacytoiddendriticcellneoplasmbpdcn AT wangeunice s139interimanalysisofaregistrationenablingstudyofpivekimabsunirinepvekimgn632acd123targetingantibodydrugconjugateinpatientswithblasticplasmacytoiddendriticcellneoplasmbpdcn AT aribiahmed s139interimanalysisofaregistrationenablingstudyofpivekimabsunirinepvekimgn632acd123targetingantibodydrugconjugateinpatientswithblasticplasmacytoiddendriticcellneoplasmbpdcn AT ulricksonmatthew s139interimanalysisofaregistrationenablingstudyofpivekimabsunirinepvekimgn632acd123targetingantibodydrugconjugateinpatientswithblasticplasmacytoiddendriticcellneoplasmbpdcn AT marconigiovanni s139interimanalysisofaregistrationenablingstudyofpivekimabsunirinepvekimgn632acd123targetingantibodydrugconjugateinpatientswithblasticplasmacytoiddendriticcellneoplasmbpdcn AT laneandrew s139interimanalysisofaregistrationenablingstudyofpivekimabsunirinepvekimgn632acd123targetingantibodydrugconjugateinpatientswithblasticplasmacytoiddendriticcellneoplasmbpdcn AT kantarjianhagop s139interimanalysisofaregistrationenablingstudyofpivekimabsunirinepvekimgn632acd123targetingantibodydrugconjugateinpatientswithblasticplasmacytoiddendriticcellneoplasmbpdcn AT slosscallum s139interimanalysisofaregistrationenablingstudyofpivekimabsunirinepvekimgn632acd123targetingantibodydrugconjugateinpatientswithblasticplasmacytoiddendriticcellneoplasmbpdcn AT malcolmkara s139interimanalysisofaregistrationenablingstudyofpivekimabsunirinepvekimgn632acd123targetingantibodydrugconjugateinpatientswithblasticplasmacytoiddendriticcellneoplasmbpdcn AT zweidlermckaypatrick s139interimanalysisofaregistrationenablingstudyofpivekimabsunirinepvekimgn632acd123targetingantibodydrugconjugateinpatientswithblasticplasmacytoiddendriticcellneoplasmbpdcn AT davernaval s139interimanalysisofaregistrationenablingstudyofpivekimabsunirinepvekimgn632acd123targetingantibodydrugconjugateinpatientswithblasticplasmacytoiddendriticcellneoplasmbpdcn |